<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940523-0-00037</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=81 g=1 f=1 --> 1. Direct Effects of Ingestion <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Calgene provided evidence that APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II is rapidly inactivated by stomach acid, is degraded by digestive enzymes, and is not modified by glycosylation (i.e., does not contain sugar molecules attached to the protein) when produced in the transgenic plants under consideration. In addition, Calgene noted that enzymes such as APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II are heat labile. Thus, Calgene concluded that APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II does not possess any of the characteristics associated with allergenic proteins such as proteolytic stability, glycosylation, or heat stability (Ref. 15). In April 1992, Calgene also conducted protein and DNA sequence comparisons using sequences in four separate databases (GenBank, EMBL, PIR 29, and Swiss-Prot) and established that APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II does not have significant homology to any proteins listed as food allergens or toxins in these databases. <!-- PJG 0012 frnewline --> FDA agrees with Calgene that the characteristics of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II do not raise a safety concern. First, each whole food, on average, contains several thousands of different proteins (Ref. 16). As a class, proteins are rarely toxic (Ref. 17) and APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II is not known to be toxic. Second, APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II is a phosphorylating enzyme, and all plants and animals that are part of the food supply contain such phosphorylating enzymes without adverse consequences. Third, APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II has been shown to be rapidly degraded under simulated gastric conditions (Refs. 18 through 21). Finally, the estimated dietary exposure to APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II is very low (480 &mu;g APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II per person per day, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 4 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  or 0.16 part per million in the diet, based on a 100-percent market share for tomatoes containing APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II (Ref. 18)). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 4 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> Because oils produced from transgenic cottonseed and rapeseed would not contribute APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II to the human diet (see also section 2 below), the exposure estimate was derived exclusively for tomatoes. The agency made several conservative assumptions in arriving at the probable per capita exposure to APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II of 480 &mu;g/person/day. For example, FDA assumed that all tomatoes contain APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II at a level of 0.1 percent of total protein although, of the two lines intended for commercialization by Calgene, one contains less than 0.01 percent and the other less than 0.002 percent of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II (as a percentage of total protein). Second, FDA included APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II in processed products in its estimate although high temperature treatment used in the production of processed products would be expected to result in loss of enzymatic activity of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II. In summary, the exposure estimate represents a theoretical maximum rather than a realistic estimate of exposure to APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Based upon the available evidence, the agency believes that this protein does not possess any properties that would distinguish it toxicologically from other phosphorylating enzymes in the food supply. Further, because of the low exposure levels and normal digestibility of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II, the agency concludes that no limits other than good manufacturing practice are needed to ensure the safety of the petitioned use of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II (Ref. 20). <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 5 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> A recently published study (Ref. 22) also showed that APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II is rapidly degraded under simulated mammalian digestive conditions. In addition, in an acute mouse feeding study, the investigations showed that feeding highly exaggerated doses of purified APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II caused no deleterious effects. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> 2. Effects on the Therapeutic Efficacy of Orally Administered Antibiotics <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> a.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II in human foods.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> i.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Relevant source of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Calgene considered whether APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II could affect the therapeutic efficacy of orally administered aminoglycoside antibiotics. In doing so, Calgene stated that only APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II from fresh tomatoes is relevant because it is the only form that is enzymatically active. Processed tomato products (such as processed whole tomatoes, chili, juice, pulp, paste, catsup, and soup) are subjected to temperatures in the range of 82 to 100  <!-- PJG 0040 degreeslatlong --> &cir;C; these temperatures would be expected to inactivate the APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II enzyme. For edible oils extracted from cottonseed and rapeseed, high temperature treatment, solvent extraction, and subsequent purification steps generally included in the processing of such oils would also be expected to inactivate APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II. <!-- PJG 0012 frnewline --> FDA agrees that high temperature treatment denatures proteins and inactivates enzymes and therefore, processed products that contain tomatoes with the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene are unlikely to contain any enzymatically active APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II. In addition, purified oils essentially do not contain protein; therefore, oils derived from transgenic cottonseed and rapeseed modified using the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene would not be expected to contain active or inactive APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II (Refs. 18 and 23). Thus, FDA agrees that fresh tomatoes from plants developed using the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene are the only source of active APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            